Firebrick Pharma (ASX:FRE) Ending Cash Position : A$0.91 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Ending Cash Position?

Firebrick Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 was A$0.91 Mil.

Firebrick Pharma's quarterly Ending Cash Position declined from Dec. 2023 (A$1.31 Mil) to Jun. 2024 (A$0.83 Mil) but then increased from Jun. 2024 (A$0.83 Mil) to Dec. 2024 (A$0.91 Mil).

Firebrick Pharma's annual Ending Cash Position declined from Jun. 2022 (A$7.14 Mil) to Jun. 2023 (A$2.36 Mil) and declined from Jun. 2023 (A$2.36 Mil) to Jun. 2024 (A$0.83 Mil).

Firebrick Pharma Ending Cash Position Historical Data

The historical data trend for Firebrick Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Ending Cash Position Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Ending Cash Position

7.14

2.36

0.83

Firebrick Pharma Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial			4.91	2.36	1.31	0.83	0.91

Firebrick Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Firebrick Pharma's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.355	+	-1.53
	=	0.83

Firebrick Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.824	+	0.082
	=	0.91

Firebrick Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines